| Abstract: |
Cancer stem cells (CSCs) are thought to be critical for the engraftment and long-term growth of many tumors, including glioblastoma (GBM). The cells are at least partially spared by traditional chemotherapies and radiation therapies, and finding new treatments that can target CSCs may be critical for improving patient survival. It has been shown that the NOTCH signaling pathway regulates normal stem cells in the brain, and that GBMs contain stem-like cells with higher NOTCH activity. We therefore used low-passage and established GBM-derived neurosphere cultures to examine the overall requirement for NOTCH activity, and also examined the effects on tumor cells expressing stem cell markers. NOTCH blockade by γ-secretase inhibitors (GSIs) reduced neurosphere growth and clonogenicity in vitro, whereas expression of an active form of NOTCH2 increased tumor growth. The putative CSC markers CD133, NESTIN, BMI1, and OLIG2 were reduced following NOTCH blockade. When equal numbers of viable cells pretreated with either vehicle (dimethyl sulfoxide) or GSI were injected subcutaneously into nude mice, the former always formed tumors, whereas the latter did not. In vivo delivery of GSI by implantation of drug-impregnated polymer beads also effectively blocked tumor growth, and significantly prolonged survival, albeit in a relatively small cohort of animals. We found that NOTCH pathway inhibition appears to deplete stem-like cancer cells through reduced proliferation and increased apoptosis associated with decreased AKT and STAT3 phosphorylation. In summary, we demonstrate that NOTCH pathway blockade depletes stem-like cells in GBMs, suggesting that GSIs may be useful as chemotherapeutic reagents to target CSCs in malignant gliomas. © AlphaMed Press. |
| Keywords: |
signal transduction; protein kinase b; cancer survival; controlled study; protein phosphorylation; unclassified drug; nonhuman; antineoplastic agents; cancer patient; brain neoplasms; ki 67 antigen; cell proliferation; biological marker; mouse; animals; mice; cell viability; gene; stat3 protein; apoptosis; tumor markers, biological; oligodendrocyte transcription factor 2; animal experiment; animal model; cohort analysis; notch receptor; transcription factor hes 1; in vivo study; neurons; in vitro study; tumor xenograft; dose-response relationship, drug; tumor cells, cultured; xenograft model antitumor assays; transfection; phosphorylation; time factors; animalia; mus musculus; cancer inhibition; dimethyl sulfoxide; nude mouse; mice, nude; neoplastic stem cells; tumor burden; enzyme inhibitors; glioblastoma; cancer stem cell; proto-oncogene proteins c-akt; peptides; stat3 transcription factor; glyceraldehyde 3 phosphate dehydrogenase; cd133 antigen; antigens, cd; bmi1 protein; nestin; glycoproteins; polymer; gamma secretase inhibitor; notch1 receptor; amyloid precursor protein secretases; receptor, notch2; clonogenesis; notch; γ-secretase inhibitor; 11 endo n (5,6,7,8,9,10 hexahydro 6,9 methanobenzo[a][8]annulen 11 yl)thiophene 2 sulfonamide; notch2 gene; spheroids, cellular
|
